North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations - 19/03/25
Doi : 10.1016/j.jaad.2024.11.071
Raed Alhusayen, MBBS, MSc (Co-Chair) a, b, ⁎ 
, Serena Dienes, BSc c, Megan Lam, MD b, Afsaneh Alavi, MD d, Ali Alikhan, MD e, Maria Aleshin, MD f, Emad Bahashwan, MD g, Steve Daveluy, MD h, Noah Goldfarb, MD i, Amit Garg, MD j, Wayne Gulliver, MD k, Tarannum Jaleel, MD, MHSc l, Alexa B. Kimball, MD, MPH m, n, Mark G. Kirchhof, MD, PhD o, p, Joslyn Kirby, MD, MS, MEd q, r, Joi Lenczowski, MD s, Hadar Lev-Tov, MD, MAS t, Michelle A. Lowes, MBBS, PhD u, Irene Lara-Corrales, MD, MSc v, Robert Micheletti, MD w, Martin Okun, MD, PhD x, Lauren Orenstein, MD, MSc y, Susan Poelman, MD z, Vincent Piguet, MD, PhD aa, Martina Porter, MD ab, Barry Resnik, MD t, ac, Cathryn Sibbald, MD, MSc b, v, Vivian Shi, MD ad, Christopher Sayed, MD ae, Se Mang Wong, MD af, Andrea Zaenglein, MD r, ag, Helene Veillette, MD ah, Jennifer L. Hsiao, MD ai, Haley B. Naik, MD, MHSc (Co-Chair) aj
, Serena Dienes, BSc c, Megan Lam, MD b, Afsaneh Alavi, MD d, Ali Alikhan, MD e, Maria Aleshin, MD f, Emad Bahashwan, MD g, Steve Daveluy, MD h, Noah Goldfarb, MD i, Amit Garg, MD j, Wayne Gulliver, MD k, Tarannum Jaleel, MD, MHSc l, Alexa B. Kimball, MD, MPH m, n, Mark G. Kirchhof, MD, PhD o, p, Joslyn Kirby, MD, MS, MEd q, r, Joi Lenczowski, MD s, Hadar Lev-Tov, MD, MAS t, Michelle A. Lowes, MBBS, PhD u, Irene Lara-Corrales, MD, MSc v, Robert Micheletti, MD w, Martin Okun, MD, PhD x, Lauren Orenstein, MD, MSc y, Susan Poelman, MD z, Vincent Piguet, MD, PhD aa, Martina Porter, MD ab, Barry Resnik, MD t, ac, Cathryn Sibbald, MD, MSc b, v, Vivian Shi, MD ad, Christopher Sayed, MD ae, Se Mang Wong, MD af, Andrea Zaenglein, MD r, ag, Helene Veillette, MD ah, Jennifer L. Hsiao, MD ai, Haley B. Naik, MD, MHSc (Co-Chair) aj a Sunnybrook Research Institute, Toronto, Ontario, Canada
b Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
c Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
d Department of Dermatology, Mayo Clinic, Rochester, Minnesota
e Sutter Medical Foundation, Sacramento, California
f Department of Dermatology, Stanford University School of Medicine, Stanford, California
g Division of Dermatology, Faculty of Medicine, University of Bisha, Bisha, Saudi Arabia
h Department of Dermatology, Wayne State University School of Medicine, Detroit, Michigan
i Department of Dermatology, University of Minnesota, Minneapolis, Minnesota
j Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York
k Department of Dermatology, Memorial University of Newfoundland, St. John's, Canada
l Department of Dermatology, Duke University School of Medicine, Durham, North Carolina
m Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
n Department of Dermatology, Harvard Medical School, Boston, Massachusetts
o Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
p Division of Dermatology, Department of Medicine, Ottawa Hospital, Ottawa, Ontario, Canada
q Incyte Corporation, Wilmington, Delaware
r Department of Dermatology, Penn State Health, Hershey, Pennsylvania
s Lenczowski Dermatology LLC, Richmond, Virginia
t Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida
u Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York
v Division of Dermatology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
w Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
x Fort HealthCare, Fort Atkinson, Wisconsin
y Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
z Division of Dermatology, University of Calgary and Beacon Dermatology, Calgary, Alberta, Canada
aa Division of Dermatology, Department of Medicine, University of Toronto and Women's College Hospital, Toronto, Ontario, Canada
ab Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
ac Resnik Skin Institute, Miami, Florida
ad Department of Dermatology, University of Washington, Seattle, Washington
ae Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
af Department of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada
ag Penn State Children's Hospital, Hershey, Pennsylvania
ah Division of Dermatology, Department of Medicine, CHU de Québec-Université Laval, Québec, Canada
ai Department of Dermatology, University of Southern California, Los Angeles, California
aj Department of Dermatology, University of California, San Francisco, California
∗Correspondence to: Raed Alhusayen, MBBS, MSc (Co-Chair), Division of Dermatology, Sunnybrook Research Institute, 2075 Bayview Ave, Toronto, Ontario M4N3M5, Canada.Divisionof DermatologySunnybrook Research Institute2075 Bayview AveTorontoOntarioM4N3M5Canada
Abstract |
Background |
Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.
Objective |
To provide evidence-based consensus recommendations for patients with HS in 7 special patient populations: (i) pregnancy, (ii) breastfeeding, (iii) pediatrics, (iv) malignancy, (v) tuberculosis infection, (vi) hepatitis B or C infection, and (vii) HIV disease.
Methods |
Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation system to ascertain level of evidence and selected through a modified Delphi consensus process.
Results |
One hundred eighteen expert consensus statements are provided for the management of patients with HS across these 7 special patient populations.
Le texte complet de cet article est disponible en PDF.Key words : antiandrogens, antibiotics, biologics, breastfeeding, comorbidity, guidelines, hepatitis B, hepatitis C, hidradenitis suppurativa, HIV, immunomodulators, immunosuppressive, malignancy, management, North America, pediatric, pregnancy, safety, therapy, tuberculosis
Abbreviations used : ART, BCG, C5a, GI, HBV, HIV, HS, IBD, ID, IGRA, IL, OCP, RCT, STI, TB, TMP-SMX, TNF, TST
Plan
| Funding sources: None. |
|
| Disclaimer: These guidelines are based on the best available evidence and expert consensus at the time of publication. They are intended to assist physicians in clinical decision-making and are not a substitute for professional medical judgment. Clinical discretion should be exercised in all patient care decisions, taking into account individual patient circumstances. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 92 - N° 4
P. 825-852 - avril 2025 Retour au numéro
Article précédent
- JAAD Game Changers: Diet in dermatology: Part I. atopic dermatitis, acne, and nonmelanoma skin cancer
- Robert T. Brodell
- Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases
- Peggy A. Wu, Jiejun Wu, Regina Liu, Sydney Sullivan, Olivia Keller, Leah Caro-Chang, Yuden Pemba, Maxwell A. Fung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?